Brokerages expect Retrophin Inc (NASDAQ:RTRX) to report $41.97 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Retrophin’s earnings. The lowest sales estimate is $39.70 million and the highest is $43.81 million. Retrophin posted sales of $38.43 million in the same quarter last year, which indicates a positive year-over-year growth rate of 9.2%. The firm is scheduled to report its next quarterly earnings results on Tuesday, May 7th.

On average, analysts expect that Retrophin will report full year sales of $174.46 million for the current fiscal year, with estimates ranging from $173.50 million to $175.49 million. For the next financial year, analysts anticipate that the business will report sales of $196.23 million, with estimates ranging from $185.60 million to $201.80 million. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that that provide coverage for Retrophin.

Retrophin (NASDAQ:RTRX) last released its quarterly earnings results on Tuesday, February 26th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.63) by $0.42. Retrophin had a negative net margin of 62.51% and a negative return on equity of 33.53%. The firm had revenue of $43.77 million for the quarter, compared to the consensus estimate of $43.54 million. During the same quarter in the previous year, the firm posted $0.07 EPS. The firm’s quarterly revenue was up 3.8% on a year-over-year basis.

Several equities research analysts have recently weighed in on RTRX shares. BidaskClub raised shares of Retrophin from a “sell” rating to a “hold” rating in a research report on Thursday, March 14th. Zacks Investment Research raised shares of Retrophin from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 27th. ValuEngine downgraded shares of Retrophin from a “strong-buy” rating to a “buy” rating in a research report on Thursday, January 17th. Svb Leerink reissued an “outperform” rating on shares of Retrophin in a research report on Tuesday, February 26th. Finally, TheStreet downgraded shares of Retrophin from a “c-” rating to a “d+” rating in a research report on Friday, February 22nd. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Retrophin currently has a consensus rating of “Buy” and an average price target of $48.00.

In other news, SVP Elizabeth E. Reed sold 1,500 shares of Retrophin stock in a transaction dated Wednesday, January 9th. The shares were sold at an average price of $23.96, for a total value of $35,940.00. Following the completion of the transaction, the senior vice president now directly owns 17,077 shares of the company’s stock, valued at approximately $409,164.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP William E. Rote sold 1,250 shares of Retrophin stock in a transaction dated Tuesday, February 19th. The shares were sold at an average price of $21.52, for a total transaction of $26,900.00. The disclosure for this sale can be found here. Insiders sold a total of 14,417 shares of company stock valued at $313,080 in the last three months. Insiders own 3.67% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC boosted its holdings in shares of Retrophin by 5.3% in the 4th quarter. Geode Capital Management LLC now owns 483,083 shares of the biopharmaceutical company’s stock valued at $10,932,000 after buying an additional 24,468 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Retrophin by 6.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,154,859 shares of the biopharmaceutical company’s stock valued at $26,134,000 after buying an additional 67,834 shares during the period. Macquarie Group Ltd. boosted its holdings in shares of Retrophin by 17.6% in the 4th quarter. Macquarie Group Ltd. now owns 2,265,924 shares of the biopharmaceutical company’s stock valued at $51,278,000 after buying an additional 339,588 shares during the period. Legal & General Group Plc boosted its holdings in shares of Retrophin by 17.2% in the 4th quarter. Legal & General Group Plc now owns 15,866 shares of the biopharmaceutical company’s stock valued at $360,000 after buying an additional 2,325 shares during the period. Finally, Metropolitan Life Insurance Co. NY boosted its holdings in shares of Retrophin by 318.5% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 13,785 shares of the biopharmaceutical company’s stock valued at $312,000 after buying an additional 10,491 shares during the period.

Retrophin stock traded down $0.55 during midday trading on Friday, hitting $22.39. 266,177 shares of the stock were exchanged, compared to its average volume of 349,674. Retrophin has a 1 year low of $19.77 and a 1 year high of $33.00. The company has a market capitalization of $949.95 million, a price-to-earnings ratio of -8.81 and a beta of 1.02. The company has a debt-to-equity ratio of 0.61, a current ratio of 4.74 and a quick ratio of 4.68.

Retrophin Company Profile

Retrophin, Inc, a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.

Featured Article: Index Funds

Get a free copy of the Zacks research report on Retrophin (RTRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Retrophin (NASDAQ:RTRX)

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.